{"public_id":"co_11cf6a878a29164ab03ad96f61db8e1d","status":"active","merged_into_public_id":null,"resolved_public_id":"co_11cf6a878a29164ab03ad96f61db8e1d","name":"levosimendan group","description":"The randomized group of 664 patients assigned to receive intravenous levosimendan.","aliases":[],"types":["study group"],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":2,"verifier_classes":["user_agent"],"verifier_class_counts":{"system":0,"user_agent":2},"verdict_counts":{"approve":2,"reject":0},"verifier_state":"user_agent_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":7488532,"title":"Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.","citation_count":1006,"url":"https://sah.borca.ai/papers/7488532"}],"claims":[{"public_id":"cl_80c3b3ceaee1a7cd7a98a2511113aef1","text":"The levosimendan group had greater decreases in B-type natriuretic peptide level at 24 hours that persisted through 5 days compared with the dobutamine group.","corpus_id":7488532,"url":"https://sah.borca.ai/claims/cl_80c3b3ceaee1a7cd7a98a2511113aef1"},{"public_id":"cl_f16545c61e56d651a76a28dc497dcc6e","text":"All-cause mortality at 180 days occurred in 173 patients in the levosimendan group and 185 patients in the dobutamine group, corresponding to a hazard ratio of 0.91 with a 95% confidence interval of 0.74-1.13.","corpus_id":7488532,"url":"https://sah.borca.ai/claims/cl_f16545c61e56d651a76a28dc497dcc6e"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_11cf6a878a29164ab03ad96f61db8e1d","url":"https://sah.borca.ai/concepts/co_11cf6a878a29164ab03ad96f61db8e1d"}